Ardsley Advisory Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Ardsley Advisory Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$246K	–	144
2018 Q3	$246K	Hold	10,000	–	–	0.03%	134
2018 Q2	$196K	Sell	10,000 -5,000	-33%	-$94.6K	0.03%	148
2018 Q1	$281K	Buy	+15,000	New	+$245K	0.04%	128

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ardsley Advisory Partners's RCKT Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Rocket Pharmaceuticals (RCKT) in Q4 2018, closing a stake of 10,000 shares — an estimated $246K sold.

Ardsley Advisory Partners first reported a position in RCKT in Q1 2018 and held it in 3 quarters. The position peaked at $281K in Q1 2018. 87 funds tracked by Wall St. Rank hold RCKT as of Q4 2018.

Ardsley Advisory Partners reported no remaining Rocket Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 10,000 Rocket Pharmaceuticals shares in Q4 2018, an estimated $246K.
Ardsley Advisory Partners first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Ardsley Advisory Partners's Rocket Pharmaceuticals position peaked at $281K in Q1 2018.
87 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.